Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spero Therapeutics ( (SPRO) ) has shared an announcement.
On June 12, 2025, Spero Therapeutics‘ stockholders approved an amendment to the company’s 2017 Stock Incentive Plan, increasing the authorized shares by 3,000,000. This decision potentially enhances the company’s ability to attract and retain talent, which could positively impact its operations and competitive positioning in the biotechnology sector.
The most recent analyst rating on (SPRO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.
Spark’s Take on SPRO Stock
According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.
Spero Therapeutics is currently facing significant financial and operational challenges, as evidenced by declining revenues, negative profit margins, and operational inefficiencies. Technical analysis suggests ongoing bearish momentum, while valuation metrics highlight financial struggles due to a negative P/E ratio. The earnings call highlighted promising developments in their tebipenem HBr program, but these are offset by setbacks in other trials and increased financial losses. The overall score reflects these mixed but predominantly negative factors.
To see Spark’s full report on SPRO stock, click here.
More about Spero Therapeutics
Spero Therapeutics operates in the biotechnology industry, focusing on developing novel therapies for bacterial infections and other diseases.
Average Trading Volume: 4,021,693
Technical Sentiment Signal: Buy
Current Market Cap: $159.3M
See more data about SPRO stock on TipRanks’ Stock Analysis page.